- Home
- ANET vs NVO Comparison
ANET vs NVO Comparison
Compare ANET & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANET | NVO |
|---|---|---|
| Founded | 2004 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.1B | 172.5B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANET | NVO |
|---|---|---|
| Price | $134.48 | $39.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $173.56 | $51.00 |
| AVG Volume (30 Days) | 5.6M | ★ 18.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.14% |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $9,005,700,000.00 | N/A |
| Revenue This Year | $28.79 | N/A |
| Revenue Next Year | $21.10 | $3.30 |
| P/E Ratio | $48.88 | ★ $13.60 |
| Revenue Growth | ★ 28.60 | N/A |
| 52 Week Low | $59.43 | $35.85 |
| 52 Week High | $164.94 | $81.44 |
Technical Indicators
Market Signals| Indicator | ANET | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 37.15 |
| Support Level | $120.77 | $35.85 |
| Resistance Level | $140.39 | $39.88 |
| Average True Range (ATR) | 4.88 | 0.88 |
| MACD | 0.12 | 0.51 |
| Stochastic Oscillator | 60.15 | 77.79 |
Price Performance
Historical ComparisonAbout ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that mainly sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-quarters of its sales from North America.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.